Compound A Hydrochloride Polymorphs for Stable Solid Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing Compound A, a selective CB2 receptor agonist, result in a non-crystalline free base form that is not suitable for drug development and formulation, lacking stability and suitable solubility characteristics.
Innovation Solution
The development of a crystalline HCl salt of Compound A, specifically in polymorph forms Pattern 1 and Pattern 2, characterized by distinct XRPD patterns and melting points, providing a stable and soluble form suitable for pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the free base form of Compound A is used, then the synthesis is straightforward, but the compound lacks crystallinity and suitable solubility characteristics for drug formulation
Solution Approach 1:
The patent applies parameter changes by converting the free base form of Compound A into salt forms (specifically hydrochloride, sulfate, and mesylate salts) through chemical reaction with appropriate acids. This transformation changes the physical and chemical parameters of the compound, resulting in crystalline forms with improved solubility characteristics and stability suitable for pharmaceutical formulation while maintaining the same molecular core structure
Solution Approach 2:
The patent uses acids (hydrochloric acid, sulfuric acid, methanesulfonic acid) as intermediaries to transform the free base Compound A into stable salt forms. These acid intermediaries facilitate the formation of crystalline structures with predictable solubility profiles, enabling the compound to meet pharmaceutical formulation requirements without altering the active pharmacophore
2Reliability
If multiple salt forms are developed, then solubility and stability are improved, but the complexity of identifying suitable forms increases
Solution Approach 1:
The patent systematically explores different salt forms by changing the counterion parameter (hydrochloride, sulfate, mesylate) to achieve desired solubility and stability profiles. Each salt form represents a controlled parameter change that can be evaluated against formulation requirements, providing a structured approach to optimizing compound properties
Solution Approach 2:
The patent identifies specific crystalline forms (Pattern 1 and Pattern 2 for hydrochloride salt) with distinct local structural qualities characterized by specific XRPD patterns. This allows selection of the most appropriate crystalline form based on local structural properties that confer desired solubility and stability characteristics for specific formulation needs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline HCl salt forms exhibit improved stability, solubility, and suitability for solid dosage forms, addressing the limitations of the non-crystalline free base form and enabling effective pharmaceutical applications.
Implementation Method 1
a powder X-ray diffraction (XRPD) pattern comprising peaks, in terms of 2-Theta, at 5.9, 6.6, 8.9, 11.8, 13.2, 14.5, 15.6, 16.0, 17.4, 18.3, 19.5, 20.2, 22.0, 26.6, and 27.0 degrees 2-Theta +/- 0.2 degrees 2-Theta
Implementation Method 2
having a melting endotherm at onset 191°C in differential scanning calorimetry (DSC) or at onset 192°C in thermogravimetry/differential thermal analysis (TG/DTA)
Data Source
Figure 1-1~1-3
Figure 1-4~1-5
Figure 1-6~1-7
AI summary
This invention relates to novel salts and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol, simply abbreviated as Compound A, which is a selective CB2 receptor agonist. The present invention provides a salt of Compound A, a crystal form thereof, a method for preparing the said salt and a pharmaceutical composition thereof and its use. The salts of Compound A of the present invention show good pharmaceutical formulation properties such as high aqueous solubility, good crystallinity, high melting point, good chemical and physical stability, or non-deliquescent.